Tuesday, 2 June 2020

Johnny Sirpilla Joins BioLargo’s Subsidiary Clyra Medical Technologies as Chief Business Development Officer

Westminster, CA – June 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that experienced business executive John A. Sirpilla has expanded his role from the Advisory Board of BioLargo’s partially owned subsidiary Clyra Medical Technologies, Inc., to serve as Clyra’s Chief Business Development Officer.

In his new role at the company, Mr. Sirpilla will work with Clyra’s senior executive team on brand expansion and retail channel development, and will work to develop strategic partnerships to help make Clyra products widely available to individuals, businesses, and the healthcare industry.

Mr. Sirpilla is the former President of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry and was promoted in 2012 to Chief Business Development Officer for the parent company, Camping World and Good Sam with annual sales of nearly $4 billion.   He is currently the CEO and founder of Encourage LLC (www.encourage33.com), a family office focused on driving change in healthy living, leadership, and child adoption. A long-time resident of Canton Ohio, Mr. Sirpilla also sits on the board of trustees of the Pro Football Hall of Fame, Hall of Fame Health, publicly traded LCI, Aultman Health Foundation, and other medical device boards.
Mr. Sirpilla joins the Clyra team as the company launches its FDA registered Clyraguard Personal Protection Spray to help protect personal protective equipment from the SARS-CoV-2 Coronavirus (COVID-19).

Mr. Sirpilla commented, “At Camping World, a portion of my responsibilities involved the oversight of call center operations, buying & merchandising, parts and accessories inventory, distribution center supply chain, store operations, and wholesale distribution. I believe strongly that these experiences will help me propel Clyra to the success it deserves. Clyra’s products fit well in my philosophy that inspiring others can lead to a positive impact on the world.”

Clyraguard is a spray designed to help prevent cross contamination by the SARS-CoV-2 Coronavirus, the cause of COVID-19 disease of the personal protective equipment worn by both front-line healthcare workers and consumers. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

More information about Clyraguard can be seen at the Clyra Medical website:  www.clyramedical.com/clyraguard


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies (www.ClyraMedical.com) offers patented and patent pending effective, and safe, advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.

In addition, Clyra offers Clyraguard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Thursday, 28 May 2020

BioLargo Granted Expanded Patent Coverage for its AOS Water Treatment Technology


Westminster, CA – May 28, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced that it has been awarded a new US patent covering its innovative water treatment technology the Advanced Oxidation System (AOS), designed and manufactured by BioLargo’s subsidiary BioLargo Water, Inc. The AOS works by generating highly reactive iodine compounds which destroy water contaminants inside the AOS, while emitting safe, clean water. Compared to many competing technologies, the AOS costs less to install and operate, eliminates certain water contaminants existing systems cannot, and requires less electricity to treat water to enable safe water discharge and/or reuse.

The new patent – US 10,654,731 B2 – grants broader coverage (meaning it has fewer specific limitations) of the AOS and its components than previous patents covering the AOS, thereby providing greater intellectual property protection to the company as it works to begin commercial trials for the AOS technology and develops strategic commercial partnerships.

BioLargo Water President Dr. Richard Smith commented, “This patent was issued at a critical time, as we are hard at work establishing the first commercial trials for the AOS technology, after which we hope to achieve initial sales. With broad, secure intellectual property protection, we can launch this powerful and innovative technology without significant concern about competitors copying our designs. This is a great day for BioLargo and BioLargo Water, and we are proud of our team members who made this possible.”

BioLargo Water currently has a crowdfunding opportunity open. To learn more about this opportunity to invest in BioLargo Water, go to www.waterworksfund.com.


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About BioLargo Water
BioLargo Water, Inc. is an Alberta-based Canadian corporation headquartered at Agri-Food Discovery Place located on campus at the University of Alberta in Edmonton. BioLargo Water, Inc. developed and is commercializing the Advanced Oxidation System (AOS), a patented and proprietary technology aimed at providing cost- and energy-efficient treatment of water and wastewater to enable practical and affordable safe discharge and reuse of diverse water sources. Learn more at www.biolargowater.com. BioLargo Water, Inc. is a subsidiary of BioLargo Water Investment Group, Inc. (BWIG), which a subsidiary of BioLargo, Inc. (www.biolargo.com), an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  BioLargo features unique disruptive solutions to deliver clean air, clean water and a clean, safe environment.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Tuesday, 26 May 2020

Shawn Dougherty Joins BioLargo’s Subsidiary Clyra Medical Technologies as Chief Revenue Officer

Westminster, CA – May 26, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that its partially owned subsidiary Clyra Medical Technologies, Inc. has recruited Shawn Dougherty, experienced C-level executive responsible for several successful high-profile product launches, to serve as Clyra’s Chief Revenue Officer.

Shawn Dougherty is an entrepreneur with substantial experience growing sales and revenues for new and innovative products. Prior to joining Clyra, Shawn co-founded mophie, the number one selling battery case manufacturer for mobile devices in North America. As COO and founder, she helped mophie create the first juice pack battery case for the iPhone in North America and built an exclusive partnership with Apple. With time, they created a solid business structure, allowing the company to thrive and withstand rapid growth, both in the U.S. and internationally. mophie raised millions of dollars in multiple rounds of capital and debt facilities. Under Shawn's guidance and strategic vision, the company grew from three employees in a barn in Michigan to a multi-million-dollar business with 300+ employees in five facilities in California, Michigan, China, Hong Kong and Amsterdam.

Shawn joins the Clyra team as the company has just launched its FDA registered Clyraguard personal protection spray to help protect non-critical personal protective equipment from the SARS-CoV-2 Coronavirus (COVID-19).

Clyraguard is a spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 Coronavirus, the cause of COVID-19 disease. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

More information about Clyraguard can be seen at the Clyra Medical website:  www.clyramedical.com/clyraguard 


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies (www.ClyraMedical.com) offers patented and patent pending effective, and safe, advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.

In addition, Clyra offers Clyraguard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Friday, 22 May 2020

Proactive Investors Interview May 22: BioLargo CEO Discusses Clyraguard




BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive that Clyraguard, a spray developed by its subsidiary Clyra Medical Technologies, was shown to cause complete inactivation of the coronavirus in lab testing.

Calvert says Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from the coronavirus.

Thursday, 21 May 2020

BioLargo’s CupriDyne Technology Proven Effective at Inactivating SARS-CoV-2

Source: Accesswire (https://www.accesswire.com/590846/BioLargos-CupriDyne-Technology-Proven-Effective-at-Inactivating-SARS-CoV-2)


Westminster, CA – May 21, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that its patented CupriDyne® technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The study was conducted by researchers at the Galveston National Laboratory (GNL), a biosafety level (BSL) level 3 lab associated with the University of Texas Medical Branch (UTMB).


To introduce a product to market that can make a COVID-19 claim, BioLargo will need approval from the Environmental Protection Agency. It has retained an EPA consultant and is considering the options to fast-track an application, including through a special Section 18 exemption. Management believes that a CupriDyne based COVID-19 product would provide a safe, environmentally friendly spray or misting product to enable effective decontamination of enclosed spaces and public places, and would provide an additional tool for protection to front-line workers and vulnerable persons as governments begin to allow businesses to reopen.

Results of the study conducted by the Galveston National Lab have been published here: https://www.biorxiv.org/content/10.1101/2020.05.08.082701v1

The study concluded:
“The novel iodine complex tested herein offers a safe and gentle alternative
to conventional disinfectants for use on indoor and outdoor surfaces.”

Dennis P. Calvert, President & CEO of BioLargo commented, “Iodine has a long history of use as a first-line disinfectant and antiviral agent, so it does not come as a surprise that CupriDyne was found to be effective against SARS-CoV-2. Research also shows that iodine-containing solutions were used in previous pandemics, including the 1918 Spanish Flu, and the SARS and MERS outbreaks in 2006 and 2013. Our products offer a unique, non-toxic and non-staining form of iodine that is exceptionally suited to help stop spread of this virus.”

About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.

The National Institute of Allergy and Infectious Diseases (NIAID) provides funding for the BSL4 laboratories and operations at the GNL, and the lab’s top priority is research to develop diagnostics, therapeutics and vaccines to combat the most dangerous diseases in the world.

Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Wednesday, 20 May 2020

Protecting People from Viruses in Water


Now and in the future, detecting and eliminating bacteria and viruses in water and wastewater may be more important than ever. Broadly, we anticipate global health pandemics will increase the need for new and existing advanced water disinfection technologies.

We’re BioLargo Water and eliminating pathogens and pollution from water is what we do.  

That’s why we’re asking you to consider joining with us by investing in BioLargo Water and our effective, affordable new treatment technology for water disinfection, the Advanced Oxidation System – AOS.

Water and wastewater can be a transmission route for bacteria and viruses.  Our AOS technology offers an effective, affordable, energy-efficient virus disinfection tool for water utilities and private businesses.  In addition, our AOS technology has been proven effective against viruses (as tested with standard virus surrogates), and we intend to help fill new market gaps for highly effective, cost-efficient solutions as they emerge.

Why consider joining us and investing in BioLargo Water and our AOS:

Our system costs less and does more.
Compared to many competing technologies, AOS: (1) costs less to install and operate; (2) allows on-site water recycling and reuse, or safe discharge; (3) eliminates contaminants and pollutants existing systems can’t; (4) hits multiple different contaminant classes with one system, rather than requiring multiple technologies; and, (5) requires less space.

We’re not starting at ground zero.
Since 2015, almost $4 million has been invested on research and development to create the BioLargo Water AOS. Funding has been primarily through industry and government partnerships.

It’s working.
Modular, compact and cost-effective, AOS succeeds where many existing technologies can't. In 2019, at a poultry processing facility pilot project, AOS-treated water met all local water re-use and discharge standards and adhered to standards of the United States Department of Agriculture (USDA) and Environmental Protection Agency (EPA).

Smart people. Powerful backing.
The BioLargo Water team of Ph.D. scientists and engineers has created a breakthrough product. Now — with the technical support, marketing and finance resources, and more, of our parent company BioLargo, Inc. — AOS stands poised to enter the wastewater market.


BioLargo Water, Inc., is led by an experienced management team with diverse talents and specialties. These exceptionally qualified PhDs and engineers are recognized as industry experts, with 20+ years of executive experience on average.

Please visit the below link and consider joining us by investing in BioLargo Water and together let’s help protect water, and us, from future viruses.


Thank you,
BioLargo Water Team

Tuesday, 19 May 2020

BioLargo Subsidiary Clyra Medical’s Clyraguard Product Shows Complete Inactivation of SARS-CoV-2 Virus in Galveston National Lab Study


Westminster, CA – May 19, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing. Testing was done under the supervision of Dr. Slobodan Paessler, DVM, PhD at the Galveston National Laboratory at the University of Texas Medical Branch at Galveston.

Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19 disease. This clear, colorless and odorless product has been extensively tested and found to be non-irritating, non-sensitizing, non-toxic, and non-staining.

More information about this exciting news can be found in Clyra Medical Technologies’ press release, linked here: http://www.globenewswire.com/news-release/2020/05/19/2035694/0/en/Clyraguard-Shows-Complete-Inactivation-of-SARS-CoV-2-Virus-in-Study-at-Galveston-National-Lab.html.

BioLargo President & CEO Dennis P. Calvert commented, “We are very proud of the Clyra team for creating this powerful tool to help fight the spread of SARS-CoV-2. Clyraguard will help protect people as we continue to fight the spread of the pandemic and will help people get back to living their lives.”

More information about Clyraguard can be seen at the Clyra Medical web site, www.clyramedical.com/clyraguard.


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies offers patented and patent pending effective, and safe advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.
In addition, Clyra offers ClyraGuard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

*Data on File

About Galveston National Laboratory/UTMB
The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.
The National Institute of Allergy and Infectious Diseases (NIAID) provides funding for the BSL4 laboratories and operations at the GNL, and the lab’s top priority is research to develop diagnostics, therapeutics and vaccines to combat the most dangerous diseases in the world.
Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.